Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) was the recipient of a significant increase in short interest in November. As of November 30th, there was short interest totalling 1,500,000 shares, an increase of 93.6% from the November 15th total of 774,700 shares. Currently, 6.7% of the company's stock are short sold. Based on an average trading volume of 16,110,000 shares, the days-to-cover ratio is currently 0.1 days.
Tevogen Bio Stock Performance
TVGN traded down $0.01 during midday trading on Thursday, reaching $1.01. 755,496 shares of the company were exchanged, compared to its average volume of 4,804,002. Tevogen Bio has a one year low of $0.26 and a one year high of $21.09. The company's fifty day moving average price is $1.44 and its 200 day moving average price is $0.91.
Insider Activity
In related news, insider Neal Flomenberg sold 1,078,600 shares of the company's stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $1.62, for a total value of $1,747,332.00. Following the sale, the insider now owns 4,254,302 shares in the company, valued at $6,891,969.24. This represents a 20.23 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 56.60% of the company's stock.
Institutional Investors Weigh In On Tevogen Bio
A hedge fund recently bought a new stake in Tevogen Bio stock. HGC Investment Management Inc. purchased a new position in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 223,077 shares of the company's stock, valued at approximately $82,000. HGC Investment Management Inc. owned 0.13% of Tevogen Bio at the end of the most recent quarter.
Tevogen Bio Company Profile
(
Get Free Report)
Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
Further Reading
Before you consider Tevogen Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tevogen Bio wasn't on the list.
While Tevogen Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
